Recent inhibition of IL-1 receptor associated kinases-4 (IRAK4), an important signaling protein involved along TLR activation pathway, showed promising results by preferentially killing CLL cells [3]. This evidence concerns the gene IRAK4 and B-cell chronic lymphocytic leukemia.